Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
about
Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunctionTreatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidenceWhat is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?The surgical management of the refractory overactive bladder.Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder SyndromeFactors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.Adverse events after botulinum A toxin injection for neurogenic voiding disorders.Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents.Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired ContractilityBotulinum toxin A in the overactive bladder: current status and future directions.Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects.Management of overactive bladder syndromeRefractory idiopathic urge urinary incontinence and botulinum A injection.Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured BladderUrodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder.Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity.Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.Botulinum toxin injection for lower urinary tract dysfunction.OnabotulinumtoxinA in the treatment of neurogenic bladder.Prospective Trial of Sacral Neuromodulation for Refractory Overactive Bladder Syndrome in Korean Patients.Current and potential urological applications of botulinum toxin A.OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.Potential applications of low-energy shock waves in functional urology.Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder.Women's perspective of botulinum toxin treatment for overactive bladder symptoms.Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment.Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.Individualizing medical treatment of overactive bladder
P2860
Q26773579-54FE5BF1-E283-40C9-8765-7370AF7FBCD2Q28304077-D01B7FC1-4684-4A25-AD96-59305B4AB80EQ30906698-D41674D3-0BC0-4987-B642-9805DC1C2BEFQ33819934-442CBCFD-8671-4159-804C-BEA45244331BQ34124059-2DC7BF15-C917-4847-8C82-67A02844793AQ35737565-B79DB4AF-309C-4E39-8224-0553692B7F48Q35908570-01488480-7D44-43F9-A412-AB696E06AD8FQ36059392-ABC8A776-1CDE-4885-8B64-18DDEA1CC9BCQ36401506-7E71E9E4-3414-4316-AECB-448FB0C75E78Q36566845-BA15D23E-46F0-4E33-B0A2-D16E9C85FABAQ36589242-6111BA3E-451D-4CA9-B6D1-BEC14B411984Q36735604-E8E75D80-0464-45D5-96C1-E8F15EC281F7Q36741471-0629EADE-CEB6-4D3D-A7AD-3D5F843F8E96Q36799110-AD9E9224-F730-4A1E-991A-622AB8D4309DQ36875672-5578C001-60AD-403E-8499-64793555873FQ37004158-4DE5E2B3-7EEC-48D0-B5F9-8FA80FEF128CQ37049870-5810593F-B146-4D73-8215-09B8BD12B443Q37682186-3935A9EB-037E-4C85-90F3-D688911ED3E8Q37812561-E7418555-E5D0-4201-A9F5-1F4DD005DB44Q37834654-42640AC6-BC32-4FD7-9B28-1903A36EE8A3Q38008697-A5CFDB14-8FEB-4271-A4F4-D08755B6888AQ38043442-426D50CB-4CE5-4257-A577-40D09E1C506FQ38434658-2826E82B-083B-4370-9E60-6CB73EE417A7Q38564108-2095861B-98E9-4A64-88C7-5987300C1106Q38669033-048888C3-681F-4DBC-B41D-5759ADE9DCF2Q39428940-24E58EFB-BB03-4473-B359-27E371944195Q40975843-184FB446-C521-477B-A5F1-6D12E584740CQ41789747-68E27CD9-4D9D-4E47-8260-645AE98EF724Q44415755-0AA05E58-ABE7-42C4-8C3B-69464D10697AQ44417435-0A9B6244-F3BC-4807-8447-65EF5EFB4959Q44739294-F5714392-B98B-40E7-822D-8E71C30A64DCQ47994885-830824B6-CED0-4D20-87DA-061415FA606CQ48279466-A012D4E8-C410-44F5-8D83-62FF4FE61C5DQ48656456-51F17BA8-DDE0-4FE9-8690-3E08D37E8055Q48744935-4F96CA40-DEA2-47B5-8BC3-05ED5792E3A2Q52923735-B651FF98-496C-40A7-9724-D993C62DD0ACQ53655799-68E0F74A-5D05-4690-BAA0-FD42C6C5F3BAQ54458418-EDD1C3BB-D29F-42AE-B3B2-54A6BBB83429Q57298524-5B7EB502-F0F2-4149-9365-F92EA33D22B3
P2860
Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Urodynamic evidence of effecti ...... ory to anticholinergic agents.
@en
Urodynamic evidence of effecti ...... ory to anticholinergic agents.
@nl
type
label
Urodynamic evidence of effecti ...... ory to anticholinergic agents.
@en
Urodynamic evidence of effecti ...... ory to anticholinergic agents.
@nl
prefLabel
Urodynamic evidence of effecti ...... ory to anticholinergic agents.
@en
Urodynamic evidence of effecti ...... ory to anticholinergic agents.
@nl
P1433
P1476
Urodynamic evidence of effecti ...... ory to anticholinergic agents.
@en
P2093
Hann-Chorng Kuo
P304
P356
10.1016/J.UROLOGY.2003.12.007
P407
P577
2004-05-01T00:00:00Z